Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Breast 1

Conditions

Epilepsy 3Small Cell Lung Carcinoma 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Neuroblastoma 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Head and Neck Neoplasms 1

Interventions

Cisplatin 253Radiotherapy 176Cetuximab 145pembrolizumab 120Docetaxel 97Fluorouracil 92Carboplatin 80Paclitaxel 77Radiotherapy, Intensity-Modulated 69Nivolumab 37Radiation 30Drug Therapy 30Erlotinib Hydrochloride 26Gemcitabine 25Cyclophosphamide 22Gefitinib 21Surveys and Questionnaires 20Standard of Care 20Surgical Procedures, Operative 19Pemetrexed 19durvalumab 18Magnetic Resonance Spectroscopy 17Capecitabine 17Radiosurgery 16Celecoxib 16atezolizumab 15Filgrastim 15Amifostine 15130-nm albumin-bound paclitaxel 15fludarabine 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Head and Neck Neoplasms × LY3295668 erbumine × Clear all
NCT03092934 2021-07-02

A Study of AK-01 (LY3295668) in Solid Tumors

Eli Lilly and Company

Phase 1/2 Completed
13 enrolled 17 charts
BreastHead & NeckThoracic

Breast Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡